ACS CAN Comments on Draft FDA Guidance on Digital Health Technologies

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) Draft Guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.